Loading patent…
AssigneeMount Sinai School of Medicine of the City University of New York
InventorsAndrei Egorov, Thomas Muster, Adolfo García-Sastre, Peter Palese, Sabine Brandt
Estimating the term…
The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.
An attenuated genetically engineered influenza A virus with an interferon-inducing phenotype wherein said virus comprises a viral genome wherein the complete NS1 coding sequences have been deleted (delNS1).
An attenuated genetically engineered influenza A virus which is infectious and replicates in an interferon (IFN) deficient cell line, wherein said virus comprises a viral genome wherein the complete NS1 coding sequences have been deleted (delNS1).
An immunogenic composition comprising an influenza A virus deINS1, in a suitable pharmaceutical composition.
Dependencies are inferred from the claim text.